Recent Phase II results for Dabogratinib, Tyra Biosciences (TYRA) experimental therapy for non-muscle invasive bladder cancer, have drawn fresh attention to the company, its late stage pipeline, and how the stock reflects that potential.

Tyra Biosciences share price has been volatile around the latest Dabogratinib update, with a 1-day share price return of 1.03% and 7-day share price return of 4.47%, set against a 30-day share price return that is down 6.47%. Across a longer window, the year-to-date share price return of 13.36% pairs with a 1-year total shareholder return of 215.37% and a 3-year total shareholder return of 81.97%. This suggests that while shorter term momentum has recently cooled, long term holders have still seen very strong gains overall.

If Tyra Biosciences has caught your eye, this is also a good moment to see how other healthcare and biotech names are trading by scanning 38 healthcare AI stocks

With Tyra Biosciences now valued at about $1.79b and trading around $30.37, while analyst targets sit higher at $51.97, investors have to ask whether there is real upside left here or if the market is already pricing in future growth.

Preferred Price-to-Book Multiple of 4.7x: Is It Justified?

With Tyra Biosciences trading around $30.37 and carrying a price-to-book (P/B) ratio of 4.7x, the stock is described as expensive compared to the broader US biotech industry, but cheaper than a closer peer set.

P/B compares the company’s market value to its net assets on the balance sheet, which is often used for early stage biotechs that have limited or no revenue. For Tyra Biosciences, a 4.7x P/B suggests investors are willing to pay several times the company’s book value, even though it currently reports no meaningful revenue and a net loss of $131.105m.

Relative to the US biotechs industry average P/B of 2.6x, Tyra Biosciences sits at a premium, which points to stronger expectations being priced into the shares than the sector overall. However, when compared with a peer group average P/B of 16.3x, the same 4.7x multiple is framed as good value, indicating the stock is trading materially below what investors have paid for similar companies in the space. See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 4.7x (ABOUT RIGHT)

However, Tyra Biosciences still carries clear risks, including its lack of revenue, an ongoing net loss of $131.105m, and reliance on successful clinical outcomes.

Next Steps

Given the mixed picture around Tyra Biosciences, with both clear risks and potential rewards in play, it makes sense to review the underlying data yourself and decide how it all fits your goals. To see both sides laid out in one place, start with 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Tyra Biosciences?

Tyra Biosciences might be on your radar, but you will miss plenty of other potential opportunities if you stop your research here. Put the Simply Wall St screener to work instead.

• Target potential value opportunities by scanning through 44 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them yet.
• Strengthen your watchlist by reviewing solid balance sheet and fundamentals stocks screener (48 results) to see which companies pair sturdier finances with room for future updates.
• Stay ahead of the crowd by checking the screener containing 18 high quality undiscovered gems that might not be widely followed but still pass robust fundamental checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.